Esperion Nominates ESP-2001 As Preclinical Development Candidate For Primary Sclerosing Cholangitis

Esperion Therapeutics, Inc. -2.76% Post

Esperion Therapeutics, Inc.

ESPR

2.82

2.83

-2.76%

+0.35% Post

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases –

– ESP-2001 Has the Potential to Meaningfully Impact the Progression of PSC, a Disease with No Approved Treatments –

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via